Mikrosatellitenanalyse und p53-Mutationsanalyse zur Responseprädiktion bei lokal fortgeschrittenen neoadjuvant therapierten Magenkarzinomen

Former published data of our group suggested that a high rate of LOH in the tumors including LOH at chromosome 17p13 might be associated with good clinical response to neoadjuvant cisplatinum-based chemotherapy in gastric cancer [1]. In this study we extended our analysis to evaluate the influence of chromosomal instability and p53-mutation on therapy response.